Biopharmaceutical Aspect of Drugs Used in Psychosis (Hallucinations and Dellusions) Associated with Parkinson’s Disease

^Authors:Maria Lettisia Meo¹, Didik Hasmono²

Department of Clinical Pharmacy, Faculty of Pharmacy,

Airlangga University, Surabaya, Indonesia

E-mail: gwae23@gmail.com

Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disease, exceeded only by Alzheimer’s disease (AD). Psychosis can be a major problem in Parkinson’s disease. Psychosis is a frequent complication of PD, and it is characterized mainly by visual hallucinations and delusions, which are often paranoid in flavor. Psychotic symptoms are present in up to 50% of patients with Parkinson’s disease. These symptoms have detrimental effects on patients’ and caregivers’ quality of life and may predict mortality. Psychosis (hallucinations and delusions) occurring in the context of Parkinson’s disease may be primary, reflecting a progression of the underlying disease process, or secondary to the use of dopaminomimetic drugs.  Attempts to reduce dopaminomimetic drugs or the initiation of antipsychotics can exacerbate motor symptoms in Parkinson’s disease with psychosis (hallucinations and dellusions). Psychosis in Parkinson’s disease (PDP) often responds to low doses of atypical neuroleptics  but adverse event but  the side effects and safety of each drugs should still be observe. Therefore the selection of appropriate therapy is expected to improve the quality of life of psychosis patients with Parkinson’s disease

Keywords: Antipsichosis, Parkinson Desease, Psychosis

Download